214 related articles for article (PubMed ID: 23235296)
1. Buprenorphine prescribing practices and exposures reported to a poison center--Utah, 2002-2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(49):997-1001. PubMed ID: 23235296
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine Exposures Among Children and Adolescents Reported to US Poison Control Centers.
Post S; Spiller HA; Casavant MJ; Chounthirath T; Smith GA
Pediatrics; 2018 Jul; 142(1):. PubMed ID: 29941678
[TBL] [Abstract][Full Text] [Related]
3. Respiratory depression following medications for opioid use disorder (MOUD)-approved buprenorphine product oral exposures; National Poison Database System 2003-2019.
Darracq MA; Thornton SL
Clin Toxicol (Phila); 2021 Apr; 59(4):303-312. PubMed ID: 32894033
[TBL] [Abstract][Full Text] [Related]
4. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians.
Arfken CL; Johanson CE; di Menza S; Schuster CR
J Subst Abuse Treat; 2010 Sep; 39(2):96-104. PubMed ID: 20598829
[TBL] [Abstract][Full Text] [Related]
5. Adult use of prescription opioid pain medications - Utah, 2008.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Feb; 59(6):153-7. PubMed ID: 20168293
[TBL] [Abstract][Full Text] [Related]
6. Specialty of prescribers associated with prescription opioid fatalities in Utah, 2002-2010.
Porucznik CA; Johnson EM; Rolfs RT; Sauer BC
Pain Med; 2014 Jan; 15(1):73-8. PubMed ID: 24118974
[TBL] [Abstract][Full Text] [Related]
7. Root causes, clinical effects, and outcomes of unintentional exposures to buprenorphine by young children.
Lavonas EJ; Banner W; Bradt P; Bucher-Bartelson B; Brown KR; Rajan P; Murrelle L; Dart RC; Green JL
J Pediatr; 2013 Nov; 163(5):1377-83.e1-3. PubMed ID: 23993129
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.
Ridge G; Gossop M; Lintzeris N; Witton J; Strang J
J Subst Abuse Treat; 2009 Jul; 37(1):95-100. PubMed ID: 19004598
[TBL] [Abstract][Full Text] [Related]
9. Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone.
Pedapati EV; Bateman ST
Pediatr Crit Care Med; 2011 Mar; 12(2):e102-7. PubMed ID: 20921918
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of continuing medical education to reduce the risk of buprenorphine diversion.
Lofwall MR; Wunsch MJ; Nuzzo PA; Walsh SL
J Subst Abuse Treat; 2011 Oct; 41(3):321-9. PubMed ID: 21664789
[TBL] [Abstract][Full Text] [Related]
11. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
[TBL] [Abstract][Full Text] [Related]
12. Understanding abuse of buprenorphine/naloxone film versus tablet products using data from ASI-MV® substance use disorder treatment centers and RADARS® System Poison Centers.
Butler SF; Black RA; Severtson SG; Dart RC; Green JL
J Subst Abuse Treat; 2018 Jan; 84():42-49. PubMed ID: 29195592
[TBL] [Abstract][Full Text] [Related]
13. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
[TBL] [Abstract][Full Text] [Related]
14. The underrecognized toll of prescription opioid abuse on young children.
Bailey JE; Campagna E; Dart RC;
Ann Emerg Med; 2009 Apr; 53(4):419-24. PubMed ID: 18774623
[TBL] [Abstract][Full Text] [Related]
15. Buprenorphine exposures in adolescents and adults: a 10-year experience of a French Poison Control Center.
Boulamery A; von Fabeck K; Glaizal M; de Haro L; Simon N
Fundam Clin Pharmacol; 2021 Aug; 35(4):764-770. PubMed ID: 33174237
[TBL] [Abstract][Full Text] [Related]
16. Unit-Dose Packaging and Unintentional Buprenorphine-Naloxone Exposures.
Wang GS; Severtson SG; Bau GE; Dart RC; Green JL
Pediatrics; 2018 Jun; 141(6):. PubMed ID: 29724879
[TBL] [Abstract][Full Text] [Related]
17. Prescription Opioid Exposures Among Children and Adolescents in the United States: 2000-2015.
Allen JD; Casavant MJ; Spiller HA; Chounthirath T; Hodges NL; Smith GA
Pediatrics; 2017 Apr; 139(4):. PubMed ID: 28320869
[TBL] [Abstract][Full Text] [Related]
18. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence.
Kissin W; McLeod C; Sonnefeld J; Stanton A
J Addict Dis; 2006; 25(4):91-103. PubMed ID: 17088229
[TBL] [Abstract][Full Text] [Related]
19. Buprenorphine for office-based treatment of patients with opioid addiction.
Manlandro JJ
J Am Osteopath Assoc; 2005 Jun; 105(6 Suppl 3):S8-13. PubMed ID: 16118361
[TBL] [Abstract][Full Text] [Related]
20. Anesthesia for patients on buprenorphine.
Bryson EO; Lipson S; Gevirtz C
Anesthesiol Clin; 2010 Dec; 28(4):611-7. PubMed ID: 21074741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
